Cubriva 25mg Tablet

Cubriva 25mg Tablet contains Brivaracetamas its active ingredient. Brivaracetam is classified as an antiepileptic drug (AED), prescribed for the management of epilepsy. It is particularly indicated for the treatment of partial-onset seizures in adults and children aged four years and older. Brivaracetam works by modulating synaptic vesicle protein 2A (SV2A), which is involved in regulating neurotransmitter release, thereby reducing the occurrence of seizures.

Uses:

Cubriva 25mg Tablet is used for the management of partial-onset seizures in patients diagnosed with epilepsy. It is usually prescribed as adjunctive therapy, meaning it is used in combination with other antiepileptic medications to enhance seizure control. Brivaracetam helps to decrease the frequency and severity of seizures, allowing patients to better manage their condition and improve their quality of life.

Dosage:

The dosage of Cubriva 25mg Tablet is determined by the healthcare provider based on various factors such as the patient’s age, weight, renal function, and response to treatment. It is usually taken orally twice daily, with or without food. The tablet should be swallowed whole with a glass of water and should not be crushed or chewed. Patients should strictly adhere to the prescribed dosage and administration instructions provided by their healthcare provider.

Side Effects:

Common side effects associated with Cubriva 25mg Tablet may include dizziness, drowsiness, fatigue, headache, nausea, vomiting, and irritability. These side effects are typically mild and transient. However, in some cases, more serious side effects such as behavioral changes, mood swings, or allergic reactions may occur. Patients should promptly report any adverse reactions to their healthcare provider.

Precautions:

Before using Cubriva 25mg Tablet, patients should inform their healthcare provider about any pre-existing medical conditions, allergies, or medications they are currently taking. Since this medication may interact with other drugs, it’s essential to review the patient’s medication regimen to prevent potential interactions. Patients with a history of psychiatric disorders should exercise caution when using Cubriva.

When Not to Use:

Cubriva 25mg Tablet is contraindicated in patients with a known hypersensitivity to Brivaracetam or any other components of the medication. It should not be used as monotherapy for epilepsy or as the initial treatment for seizures. Patients with a history of significant psychiatric disorders or suicidal ideation should also avoid this medication.